[go: up one dir, main page]

ATE360031T1 - Chimäre proteine und anwendungen - Google Patents

Chimäre proteine und anwendungen

Info

Publication number
ATE360031T1
ATE360031T1 AT01939973T AT01939973T ATE360031T1 AT E360031 T1 ATE360031 T1 AT E360031T1 AT 01939973 T AT01939973 T AT 01939973T AT 01939973 T AT01939973 T AT 01939973T AT E360031 T1 ATE360031 T1 AT E360031T1
Authority
AT
Austria
Prior art keywords
cell
proteins
disclosed
trans signal
chimeric proteins
Prior art date
Application number
AT01939973T
Other languages
English (en)
Inventor
Mark L Tykocinski
Jui-Han Huang
Original Assignee
Tr Associates L L C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tr Associates L L C filed Critical Tr Associates L L C
Application granted granted Critical
Publication of ATE360031T1 publication Critical patent/ATE360031T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01939973T 2000-01-03 2001-01-03 Chimäre proteine und anwendungen ATE360031T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17425800P 2000-01-03 2000-01-03

Publications (1)

Publication Number Publication Date
ATE360031T1 true ATE360031T1 (de) 2007-05-15

Family

ID=22635474

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01939973T ATE360031T1 (de) 2000-01-03 2001-01-03 Chimäre proteine und anwendungen

Country Status (10)

Country Link
US (1) US7569663B2 (de)
EP (2) EP1248645B1 (de)
JP (1) JP4723782B2 (de)
AT (1) ATE360031T1 (de)
AU (1) AU2926401A (de)
CA (1) CA2395945C (de)
DE (1) DE60127933T2 (de)
ES (1) ES2391760T3 (de)
IL (2) IL150571A0 (de)
WO (1) WO2001049318A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
EE200100372A (et) 1999-01-15 2002-10-15 Biogen, Incorporated TWEAK-valgu ja TWEAK-valgu retseptori antagonistid ja nende kasutamine immuunhaiguste raviks
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
AU5951901A (en) * 2000-05-08 2001-11-20 Biogen Inc Method for promoting neovascularization
US7208151B2 (en) * 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
CN106421778A (zh) 2002-04-09 2017-02-22 比奥根Ma公司 用于治疗tweak相关病症的方法
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
WO2005012363A1 (ja) * 2003-08-01 2005-02-10 Mochida Pharmaceutical Co., Ltd. 標的化された炎症惹起剤
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
ES2432564T3 (es) 2005-05-10 2013-12-04 Biogen Idec Ma Inc. Tratamiento y evaluación de trastornos inflamatorios
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
JP5600588B2 (ja) 2007-06-01 2014-10-01 ユニバーシティー オブ メリーランド，ボルティモア 免疫グロブリン定常領域Ｆｃ受容体結合因子
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
EP2362783A2 (de) 2008-10-31 2011-09-07 Biogen Idec MA Inc. Licht-targeting-moleküle und ihre anwendungen
HUE034832T2 (hu) * 2008-12-09 2021-12-28 Hoffmann La Roche Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
US9221895B2 (en) 2009-03-13 2015-12-29 The Trustees Of The University Of Pennsylvania OX40/TRAIL fusion proteins
HUE044869T2 (hu) 2010-07-28 2019-12-30 Gliknik Inc Természetes humán fehérje fragmensek fúziós fehérjéi rend szerint multimerizált immunglobulin FC kompozíciók elõállítására
CN103153332A (zh) * 2010-09-28 2013-06-12 卡尔医疗有限公司 用于治疗血液恶性肿瘤的组合物和方法
CN114835823A (zh) 2011-07-29 2022-08-02 宾夕法尼亚大学董事会 转换共刺激受体
CA2899433A1 (en) * 2012-01-27 2013-08-01 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
CA2882296A1 (en) 2012-08-20 2014-02-27 Gliknik Inc. Molecules with antigen binding and polyvalent fc gamma receptor binding activity
EP3653212B1 (de) 2012-12-20 2023-04-26 Purdue Research Foundation Chimären antigenrezeptor exprimierende t-zellen als antikrebsmittel
CA2896989A1 (en) * 2013-01-01 2014-07-10 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
WO2014121085A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Pd-l1 and pd-l2-based fusion proteins and uses thereof
WO2014121099A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
JP2018510214A (ja) * 2015-03-03 2018-04-12 カール メディカル リミテッド 二重シグナル伝達タンパク質（ｄｓｐ）融合タンパク質、及び疾患を処置するためのその使用方法
CN106046170B (zh) * 2015-04-10 2020-07-10 中国医学科学院药物研究所 一种新型trail融合蛋白
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
PT3325011T (pt) 2015-07-24 2021-01-27 Gliknik Inc Proteínas de fusão de fragmentos de proteína humana para criar composições de fc de imunoglobulina multimerizadas ordenadamente com ligação a complemento melhorada
EP3356393A4 (de) 2015-10-01 2019-08-07 Heat Biologics, Inc. Zusammensetzungen und verfahren zum angrenzen von typ i und typ ii extrazellularen domänen als heterologe chimäre proteine
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
CN110177802A (zh) 2016-12-09 2019-08-27 格利克尼克股份有限公司 多聚化stradomer GL-2045的制造优化
IL266988B2 (en) 2016-12-09 2024-11-01 Gliknik Inc Methods of treating inflammatory disorders with multivalent fc compounds
KR102597943B1 (ko) 2017-01-05 2023-11-06 카 메디컬 리미티드 Pd1-41bbl 융합 단백질 및 이의 이용 방법
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
HUE057326T2 (hu) 2017-01-05 2022-04-28 Kahr Medical Ltd SIRP1 Alfa-41 BBL fúziós fehérje és eljárások annak alkalmazására
WO2018127918A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A sirp alpha-cd70 fusion protein and methods of use thereof
EP3579870A4 (de) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Auf car-t-zell-tumor (ctct) abzielende phospholipidether (ple)-wirkstoffe
CN118184797A (zh) 2017-02-27 2024-06-14 沙塔克实验室有限公司 基于vsig8的嵌合蛋白
AU2018223822A1 (en) 2017-02-27 2019-07-11 Shattuck Labs, Inc. CSF1R-based chimeric proteins
EP3585425A4 (de) 2017-02-27 2020-10-28 Shattuck Labs, Inc. Verfahren zur herstellung und verwendung extrazellulärer domänenbasierter chimärer proteine
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
CN107267619A (zh) * 2017-07-04 2017-10-20 武汉波睿达生物科技有限公司 一种检测靶向cd33的cart细胞中car表达的荧光定量试剂盒
MA50360A (fr) 2017-10-10 2020-08-19 Alpine Immune Sciences Inc Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations
EP3735417A1 (de) 2018-01-03 2020-11-11 Alpine Immune Sciences, Inc. Immunmodulatorische multidomänenproteine und verfahren zu deren verwendung
CA3089319A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
WO2019156795A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
TW202000229A (zh) 2018-02-23 2020-01-01 美商安德賽特公司 Car t細胞療法之順序方法
CA3104780A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
JP2021531265A (ja) 2018-07-11 2021-11-18 カール メディカル リミテッド Ｐｄ１−４−１ｂｂｌバリアント融合タンパク質及びその使用方法
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
WO2021005599A1 (en) 2019-07-11 2021-01-14 Kahr Medical Ltd. Heterodimers and methods of use thereof
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
WO2023019251A1 (en) * 2021-08-12 2023-02-16 Baylor College Of Medicine Engineered soluble decoy receptors to enhance cancer immunotherapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2110518C (en) * 1991-06-27 2007-05-22 Peter S. Linsley Ctla4 receptor, fusion proteins containing it and uses thereof
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6632789B1 (en) * 1994-04-29 2003-10-14 The United States Of America As Represented By The Secretary Of The Navy Methods for modulating T cell responses by manipulating intracellular signal transduction
GB9523469D0 (en) * 1995-11-16 1996-01-17 Sandoz Ltd Organic compounds
AU2527397A (en) * 1996-03-13 1997-10-01 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
JP4751493B2 (ja) * 1996-03-20 2011-08-17 ブリストル−マイヤーズ スクイッブ カンパニー Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物
US6060054A (en) * 1996-04-10 2000-05-09 National Jewish Medical And Research Center Product for T lymphocyte immunosuppression
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.

Also Published As

Publication number Publication date
ES2391760T3 (es) 2012-11-29
CA2395945A1 (en) 2001-07-12
CA2395945C (en) 2013-12-24
IL150571A (en) 2010-11-30
JP2003521485A (ja) 2003-07-15
AU2926401A (en) 2001-07-16
WO2001049318A1 (en) 2001-07-12
EP1248645A1 (de) 2002-10-16
EP1908780B1 (de) 2012-08-15
JP4723782B2 (ja) 2011-07-13
EP1248645B1 (de) 2007-04-18
EP1248645A4 (de) 2003-08-06
US7569663B2 (en) 2009-08-04
IL150571A0 (en) 2003-02-12
DE60127933D1 (de) 2007-05-31
EP1908780A1 (de) 2008-04-09
DE60127933T2 (de) 2008-02-07
US20030216546A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
ATE360031T1 (de) Chimäre proteine und anwendungen
UA90657C2 (ru) Ловушки vegf и их терапевтические применения
CY1107351T1 (el) Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης
AU2003228962A1 (en) Ferritin fusion proteins for use in vaccines and other applications
EP2277889A3 (de) Fusionsproteine von Albumin und Interferon beta
WO2005021579A3 (en) Epo mimetic peptides and fusion proteins
AU2002305450A1 (en) Proteomimetic compounds and methods
CY1108489T1 (el) Παραγωγη τετρασθενων αντισωματων
DE602004011770D1 (de) Fusionsproteine
ATE196650T1 (de) Stabile bakterizide proteine, welche die permeabilität erhöhen und pharmazeutische zusammensetzungen, diese enthaltend
EP1832599A3 (de) Albuminfusionsproteine
EP1005376A4 (de) Methoden und zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
DE60037978D1 (de) Interferon ähnliche moleküle, und deren verwendungen
WO2001040313A3 (en) Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
WO2005054286A3 (en) Interleukin-11 fusion proteins
WO2003014293A3 (en) Novel polypeptide analogs and fusions and their methods of use
ATE278011T1 (de) Human dnase ii
AU2002246455A1 (en) Fusion proteins for specific treatment of cancer and auto-immune diseases
DE69529235D1 (de) Menschliche dnase i varianten
MXPA03010739A (es) Moleculas de marcador endotelial tumoral 7-alfa y uso de las mismas.
WO2004011638A3 (en) Deoxyuridine 5' triphosphate nucleotidohydrolase polypeptides and structures
WO2002050116A3 (en) Adhesion molecule protein
AU2001288284A1 (en) 14189, a human kinase and uses thereof
WO2002046380A3 (en) Protein kinase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties